- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 30.09. | Why Traws Pharma Is Rising In Pre-market? | ||
| 30.09. | Alterity Therapeutics Appoints Abby Macnish Niven To Succeed Phillip Hains As CFO | ||
| 30.09. | Precision BioSciences Reports CTA Submissions For PBGENE-HBV | ||
| 30.09. | BioCryst Awarded $69 Mln RAPIVAB Contract By US Government Yo Treat Influenza | ||
| 30.09. | TTEC Receives Unsolicited Offer From CEO Kenneth Tuchman To Be Taken Private At $6.85/Shr | ||
| 30.09. | Wesdome Gold Mines Names Guy Belleau COO | ||
| 30.09. | Diversified Healthcare To Sell 18 Triple Net Leased Senior Living Communities To Brookdale | ||
| 30.09. | Frasers Offers To Buy Remaining Stake In Mulberry For 130p/share In Cash | ||
| 30.09. | Investment Evolution Credit Chairman And CEO Paul Mathieson Resigns; Names Marc Howells CEO | ||
| 30.09. | Playtech HY Profit Rises | ||
| 30.09. | Genentech To Acquire Portfolio Of Next-generation CDK Inhibitors From Regor | ||
| 30.09. | Addex Therapeutics Turns To Net Profit In Q2; Income Down | ||
| 30.09. | Payfare Explores Strategic Options Incl. Potential Sale Or Merger | ||
| 30.09. | Spotify Service Restored After Brief Outage | ||
| 30.09. | Brookdale To Acquire 18 Triple Net Leased Senior Living Communities From DHC For $135 Mln | ||
| 29.09. | Enliven Therapeutics Updates Positive Phase 1 Data For ELVN-001 In Chronic Myeloid Leukemia Patients | ||
| 27.09. | Sandvik Divests Non-Strategic Businesses To Focus On Core Operation | ||
| 27.09. | Establishment Labs Jumps In Pre-market On FDA Approval Of Its Motiva Breast Implants | ||
| 27.09. | Coherent Divests Newton Aycliffe Plant | ||
| 27.09. | EnVVeno Medical Announces Pricing Of Public Offering | ||
| 27.09. | Toyota Global Production, Sales Down In August; Stock Dips In Pre-market | ||
| 27.09. | Totally Continues To Trade In Line With View, Wins New Contracts; Stock Up | ||
| 27.09. | Mutares Management: Supervisory Board Extends CEO Robin Laik's Management Board Contract | ||
| 27.09. | SEC Announces $40 Mln Settlement With Cassava Sciences Over Misleading Alzheimer's Trial Statements | ||
| 27.09. | Travere Therapeutics Pauses Enrollment In Phase 3 Study Of Pegtibatinase For Manufacturing Scale-Up |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
